Compared to human programmed cell death-ligand 1 (PD-L1)-targeting mAb or vascular endothelial growth factor receptor type 1 domain 2 (VEGFR1D2) fusion protein alone, the HB0025 that combines the VEGFR1D2 and anti-PD-L1 mAb was more effective at preventing the growth of tumor (48). The gene discussed is CD274; the disease is neoplasm.